Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.60 |
| ▸ | NPC1 | O15118 | 10/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.60 |
| ▸ | GAA | P10253 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | HPGD | P15428 | 5/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KIT | P10721 | 2/20 | 0.53 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770055 | 0.84 | MAPT (0.62) | RAB9ANPC1KDM4EGAASMN1; SMN2 | |
| SCHEMBL769663 | 0.84 | RAB9A (0.58) | RAB9ANPC1KDM4EGAASMN1; SMN2 | |
| SCHEMBL769865 | 0.81 | MAPT (0.69) | RAB9ANPC1KDM4EGAASMN1; SMN2 | |
| SCHEMBL770092 | 0.80 | RAB9A (0.61) | RAB9ANPC1KDM4EGAASMN1; SMN2 | |
| SCHEMBL770131 | 0.78 | RAB9A (0.58) | RAB9ANPC1KDM4EGAASMN1; SMN2 | |
| SCHEMBL770102 | 0.76 | MAPT (0.70) | RAB9ANPC1KDM4EGAASMN1; SMN2 | |
| SCHEMBL770038 | 0.75 | MAPT (0.72) | RAB9ANPC1KDM4EGAASMN1; SMN2 | |
| SCHEMBL769029 | 0.74 | RAB9A (0.68) | RAB9ANPC1KDM4EGAASMN1; SMN2 | |
| SCHEMBL769848 | 0.73 | MAPT (0.69) | RAB9ANPC1KDM4EGAASMN1; SMN2 | |
| SCHEMBL769090 | 0.73 | KIT (0.77) | RAB9ANPC1KDM4EGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871746-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2014-10-28 | — | — | US | claimed |
| US-20120071447-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES INC. (US) | 2012-03-22 | — | — | US | claimed |
| US-8871746-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871746-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871746-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120071447-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071447-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071447-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071447-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | ZC3HAV1, GZMB, GTF3C3 | RAB9A 3973/4885NPC1 337/4885KDM4E 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.